Recent Updates
Recently added Catalysts
DERM Positive Sentiment

Journey Medical Corporation to Participate in September 2026 Investor Conferences

Key Takeaway: Journey Medical Corporation announced its participation in two investor conferences in September 2026. CEO Claude Maraoui will present at the Lake Street Capital Markets 10th Annual Best Ideas Growth Conference and the H.C. Wainwright 28th Annual Global Investment Conference. The company focuses on FDA-approved dermatological products and will provide a webcast of its presentation.

Market Sentiment Analysis

POSITIVE FACTORS

  • Journey Medical is actively participating in investor conferences.
  • The company is focused on FDA-approved dermatological treatments.
  • Leadership is engaging with investors, indicating confidence in growth.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+83%
120-day peak, hindsight
Typical move
13.9%
average across 3 past catalysts
Cash runway
~44 mo
Low dilution risk
Lead asset
DFD-29 Fasting
Phase 1 · Pharmacokinetics

Full Press Release Details

SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences.
Details of the events are as follows:
Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference Date: Thursday, September 10, 2026 Location: New York City Format: 1x1 Meetings
H.C. Wainwright 28th Annual Global Investment Conference Date and Time: Monday, September 14, 2026, at 10:00 a.m. ET Location: New York City Format: Presentation and 1x1 Meetings
A webcast of the Company’s presentation at H.C. Wainwright will be available on the News and Events page of the Investors section of Journey Medical’s website, www.journeymedicalcorp.com, for approximately 30 days after the meeting.
About Journey Medical Corporation Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical”) is a commercial-stage pharmaceutical company that primarily focuses on developing, selling and marketing FDA-approved prescription pharmaceutical products for the treatment of dermatological conditions through its efficient sales and marketing model. The Company currently markets nine branded FDA-approved prescription drugs that help treat and heal common skin conditions. The Journey Medical team comprises industry experts with extensive experience in developing and commercializing some of dermatology’s most successful prescription brands. Journey Medical is located in Scottsdale, Arizona and was founded by Fortress Biotech, Inc. (Nasdaq: FBIO). Journey Medical’s common stock is registered under the Securities Exchange Act of 1934, as amended, and the company files periodic reports with the U.S. Securities and Exchange Commission (“SEC”). For additional information about Journey Medical, visit www.journeymedicalcorp.com.

Company Contact: Jaclyn Jaffe Journey Medical Corporation (781) 652-4500 ir@jmcderm.com

Media Relations Contact: Tony Plohoros 6 Degrees (908) 591-2839 tplohoros@6degreespr.com

Frequently Asked Questions

Who is participating in the investor conferences?

Claude Maraoui, the CEO of Journey Medical, will participate.

When are the investor conferences scheduled?

The conferences are on September 10 and September 14, 2026.

Where will the conferences take place?

Both conferences will be held in New York City.

What is the focus of Journey Medical Corporation?

Journey Medical focuses on FDA-approved prescription products for dermatological conditions.

Will there be a webcast of the presentation?

Yes, a webcast will be available for 30 days after the H.C. Wainwright conference.

Last updated: Sep 8, 2026